AR040434A1 - Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco - Google Patents

Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Info

Publication number
AR040434A1
AR040434A1 AR20030102454A ARP030102454A AR040434A1 AR 040434 A1 AR040434 A1 AR 040434A1 AR 20030102454 A AR20030102454 A AR 20030102454A AR P030102454 A ARP030102454 A AR P030102454A AR 040434 A1 AR040434 A1 AR 040434A1
Authority
AR
Argentina
Prior art keywords
weight
pharmaceutical composition
farmaco
distribution
filler
Prior art date
Application number
AR20030102454A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR040434A1 publication Critical patent/AR040434A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen composiciones farmacéuticas que poseen una distribución y potencia de fármaco uniforme, que utilizan lasofoxifeno como ingrediente activo, y que contienen un dióxido de silicio para reducir la pérdida de ingrediente activo durante el proceso de fabricación, y métodos para fabricar estas composiciones. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende un núcleo de comprimido o relleno de cápsulas, conteniendo el núcleo o relleno aproximadamente 0,3% en peso a aproximadamente 14,0% en peso de (-)-cis-6-fenil-5[4-(2-pirrolidin-1-il-etoxi)fenil]-5, 6, 7, 8-tetrahidronaftalen-2-ol; un profármaco del mismo, o un asal, hidrato o solvato farmacéuticamente aceptable del compuesto o del profármaco, aproximadamente 3,% en peso de un disgregante, aproximadamente 0,5% en peso de un deslizante, aproximadamente 1,0% en peso de un lubricante y aproximadamente 81,0% en peso a aproximadamente 95,0% en peso de un diluyente/carga.
AR20030102454A 2002-07-10 2003-07-08 Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco AR040434A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39509002P 2002-07-10 2002-07-10

Publications (1)

Publication Number Publication Date
AR040434A1 true AR040434A1 (es) 2005-04-06

Family

ID=30115812

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102454A AR040434A1 (es) 2002-07-10 2003-07-08 Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Country Status (36)

Country Link
US (2) US20040057992A1 (es)
EP (1) EP1534248B1 (es)
JP (2) JP4446446B2 (es)
KR (1) KR100782693B1 (es)
CN (1) CN100344278C (es)
AP (1) AP2005003201A0 (es)
AR (1) AR040434A1 (es)
AT (1) ATE550017T1 (es)
AU (1) AU2003247017B2 (es)
BR (1) BR0312563A (es)
CA (1) CA2489407C (es)
CY (1) CY1112892T1 (es)
DK (1) DK1534248T3 (es)
EA (1) EA007268B1 (es)
EC (1) ECSP055528A (es)
ES (1) ES2395123T3 (es)
HK (1) HK1077747A1 (es)
HN (1) HN2003000206A (es)
HR (1) HRP20041196A2 (es)
IL (2) IL165746A0 (es)
IS (1) IS7594A (es)
MA (1) MA27318A1 (es)
MX (1) MXPA05000394A (es)
NO (1) NO20050018L (es)
NZ (1) NZ537278A (es)
OA (1) OA12883A (es)
PA (1) PA8576201A1 (es)
PE (1) PE20040104A1 (es)
PL (1) PL374913A1 (es)
PT (1) PT1534248E (es)
SI (1) SI1534248T1 (es)
TN (1) TNSN05006A1 (es)
TW (1) TW200406222A (es)
UY (1) UY27886A1 (es)
WO (1) WO2004006895A1 (es)
ZA (1) ZA200410196B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2006105806A1 (en) * 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
SI1878426T1 (sl) * 2005-04-26 2010-09-30 Dainippon Sumitomo Pharma Co Granulatni pripravek ki vsebuje bigvanidno spojino
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
AP2986A (en) 2007-02-23 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CA2835910C (en) * 2007-04-25 2016-06-28 Warner Chilcott Company, Llc Improved vitamin d content uniformity in pharmaceutical dosage forms
US20110092598A1 (en) * 2007-10-10 2011-04-21 Nandu Deorkar Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20090274757A1 (en) * 2008-05-01 2009-11-05 Wyeth Pharmaceutical polish formulations
WO2009135179A2 (en) * 2008-05-02 2009-11-05 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US20130172376A1 (en) * 2011-10-17 2013-07-04 Jinling Chen Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
PL2851075T3 (pl) 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
JP2016531151A (ja) * 2013-09-13 2016-10-06 バイエル ファーマ アクチエンゲゼルシャフト レファメチニブを含有する医薬組成物
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
CN109789095A (zh) * 2016-07-25 2019-05-21 Ebbu 公司 新的大麻片剂配方和组合物及其制造方法
SG11201903236SA (en) 2016-10-11 2019-05-30 Univ Duke Lasofoxifene treatment of er+ breast cancer
US11497730B2 (en) 2018-04-10 2022-11-15 Duke University Lasofoxifene treatment of breast cancer
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) * 2022-02-18 2022-04-08 山东新时代药业有限公司 一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182A (en) * 1845-09-09 Island
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
KR200161927Y1 (ko) * 1997-08-26 1999-12-01 윤종용 냉장고
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (en) * 2000-03-10 2001-11-14 Pfizer Products Inc. Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
ATE367152T1 (de) * 2001-05-01 2007-08-15 Pfizer Prod Inc Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Also Published As

Publication number Publication date
KR20050017102A (ko) 2005-02-21
SI1534248T1 (sl) 2012-07-31
WO2004006895A1 (en) 2004-01-22
ECSP055528A (es) 2005-03-10
AU2003247017B2 (en) 2008-03-06
ES2395123T3 (es) 2013-02-08
IS7594A (is) 2004-12-13
UY27886A1 (es) 2004-02-27
CY1112892T1 (el) 2016-04-13
IL165746A (en) 2008-12-29
CA2489407A1 (en) 2004-01-22
CN100344278C (zh) 2007-10-24
CN1668285A (zh) 2005-09-14
CA2489407C (en) 2009-01-27
AP2005003201A0 (en) 2005-03-31
EP1534248A1 (en) 2005-06-01
MXPA05000394A (es) 2005-03-23
PE20040104A1 (es) 2004-02-27
EA007268B1 (ru) 2006-08-25
JP2005535671A (ja) 2005-11-24
US20070110800A1 (en) 2007-05-17
TW200406222A (en) 2004-05-01
PA8576201A1 (es) 2004-05-26
TNSN05006A1 (fr) 2007-05-14
NZ537278A (en) 2007-07-27
OA12883A (en) 2006-09-15
PT1534248E (pt) 2012-05-25
US20040057992A1 (en) 2004-03-25
ZA200410196B (en) 2006-07-26
JP2007031451A (ja) 2007-02-08
HK1077747A1 (en) 2006-02-24
BR0312563A (pt) 2005-04-19
JP4446446B2 (ja) 2010-04-07
AU2003247017A1 (en) 2004-02-02
HRP20041196A2 (en) 2005-04-30
DK1534248T3 (da) 2012-06-25
ATE550017T1 (de) 2012-04-15
PL374913A1 (en) 2005-11-14
NO20050018L (no) 2005-01-12
KR100782693B1 (ko) 2007-12-07
EP1534248B1 (en) 2012-03-21
EA200401583A1 (ru) 2005-06-30
US7553500B2 (en) 2009-06-30
MA27318A1 (fr) 2005-05-02
HN2003000206A (es) 2004-07-27
IL165746A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
AR040434A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
TW200745111A (en) New compounds
TW200606164A (en) New compounds
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
AR039335A1 (es) Tableta de carga de droga alta
TW200613243A (en) Novel compounds
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
BRPI0315315B8 (es)
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
GB0112348D0 (en) Compounds
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
TW200503775A (en) Pharmaceutical composition and method for treating
TW200800984A (en) New compounds
DE602004011966D1 (en) Heterocyclylverbindungen
AR043822A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
GB0109122D0 (en) Novel compounds
EE05723B1 (et) Stabiilse koostisega ravimkoostis, mis sisaldab amlodipiini ja bisoprolooli, ning meetod selle valmistamiseks
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MY153713A (en) A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate
SE0102440D0 (sv) New compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal